Naltrexone/fluoxetineAlternative Names: Fluoxetine/naltrexone; OREX-004
Latest Information Update: 12 Jan 2009
At a glance
- Originator Orexigen Therapeutics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obsessive-compulsive disorders
Most Recent Events
- 22 Aug 2008 Preclinical trials in Obsessive-compulsive disorders in USA (PO)